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raised as to whether there is common genetic susceptibility connection 
between the two diseases, considering the risk associated with tobacco 
smoking or independent of it.
Similarly, there is a growing amount of data pointing to differences 
between the sexes, regarding the pattern of disease, its morbidity, the 
response to interventions or therapy, and mortality from primary lung 
cancer. The task of present and future research is to elucidate answers 
to these questions on the basis of different biology and genetics. 
A certain degree of confusion was introduced through indiscriminate 
and sometimes inappropriately interchanged uses of the terms sex and 
gender. Both gender and sex linked factors relate to risk of developing 
lung cancer and therapeutic implications.
In gender related risk factors, smoking plays a major role, probably in 
girls and boys as well as in adult women and men. In both youth and 
adulthood, the type of tobacco used as much as the way of smoking 
play a role. There are however other risk factors, including environ-
mental tobacco smoke, cooking fuels and fumes, employment, environ-
mental pollution, and nutrition. Each of these might interact also with 
sex-linked factors. 
The sex linked factors will generate biological differences on one hand, 
and genetic ones, on the other. 
The biological differences are rooted mostly in reproductive hormones. 
Several factors have to be considered in risk assessment like the onset 
of menarch, length of menstrual cycle, and use of hormone replacement 
therapy. Estrogens are probably playing a role in lung tumorigenesis 
at many levels. They may act as ligands to estrogen receptors activat-
ing cellular proliferation pathways. They may also undergo metabolic 
activation to reactive intermediates resulting in formation of DNA 
adducts or cause oxidative damage. Estrogen receptor beta (ER-beta) 
is the primary receptor expressed in lung tumors and studies suggest its 
activation inﬂuences lung tumor cell proliferation. On the other hand 
there no sex difference in expression of this receptor which suggests 
that this might not be dependent on the level of endogenous estrogens. 
Interaction between the ER-beta and Epidermal Growth Factor Recep-
tor (EGFR) might have therapeutic implications. Each and every one 
of these, however, is also dependent on the age of the subject as well 
as smoking status and interaction of the inhaled substances on the hor-
monal metabolism. These complicated data then, should be taken into 
account when planning recruitment and sample size of a given study. 
Sex-linked factors also inﬂuence the genetic differences between men 
and women. Women are more likely than men to carry various genetic 
mutations which, similar to biological differences, will be reﬂected 
in risk assessment, increased susceptibility to develop lung cancer on 
one hand, and response to therapy on the other. Here, once more, the 
increased risk for women can be inﬂuenced by tobacco smoking effects 
through nicotine and metabolism of other carcinogens and their interac-
tion with hormonal effects.
Two classes of enzymes are crucial in the metabolism of tobacco-relat-
ed carcinogens-the phase I and phase II enzymes. The phase I enzymes 
responsible for activation of carcinogens to reactive intermediates 
are counterbalanced by phase II enzymes having a salutary effect of 
converting these reactive intermediates to inactive conjugates which 
then can be eliminated. The toxic intermediates bind to the DNA form-
ing detectable DNA adducts. Increased levels of DNA adducts were 
found in women with lung cancer then in men. This increase in adducts 
was correlated with expression of cytochrome P450s (CYP1A1) and 
glutathione-S- transferases (GST) polymorphism associated with 
metabolic activity of detoxiﬁcation (phase II) enzymes and also induc-
tion of p53 mutations ( higher G-to-T transversion). The p53 mutations 
then contribute to perpetuation of DNA damage. Among lung cancer in 
never smokers a different pattern of mutations of p53 was found in men 
and women.
There appears to be also a pivotal role of DNA adducts on K ras muta-
tion which are more prevalent ( after controlling for tobacco effects) in 
women and associated predominantly with adenocarcinomas. 
Series of various genetic mutations are considered as putative factors 
in increased carcinogenesis or development of speciﬁc type of lung 
cancer. Other genetic factors are potentially responsible for variability 
in DNA repair mechanism and decreased recovery from DNA damage 
as well as sensitivity or resistance to chemotherapy or other responses 
to therapeutic modalities. 
The removal of damaged DNA segments or repair of mismatched 
nucleotides is controlled by a complex family of proteins. Recent stud-
ies suggest that the capacity of repair of the DNA is lower in younger 
patients with family history of lung cancer and in women. Paradoxical-
ly also this reduced repair might be responsible for development of less 
resistance to platinum based chemotherapy since the effects of platinum 
is through formation of DNA adducts leading to arrest of proliferation 
cycle and apoptosis. Studies demonstrating reduction of DNA repair 
suggest better outcome and less development of resistance to therapy.
EGFR mutations (primarily in exons 18, 19, 21) are associated with 
increased response rate to tyrosine kinase inhibitors (TKIs). The rate 
of mutations decreases with smoking they are apparently expressed 
more in women of East Asian origin where there are also reports of 
increased therapeutic responses. At the same time the toxicity from 
treatment with EGFR inhibitors (neurosensory, nausea, vomiting, alo-
pecia and neuro-psychiatric) was recorded to be higher in women then 
men. Bronchoalveolar carcinoma in non smokers is diagnosed more 
frequently in women then men and women also show better response to 
therapy with TKI inhibitors.
The association between male-female ratio and survival from lung can-
cer has been better documented then the association of the ratio with 
incidence of the disease. Overall women’s stage-for-stage improved 
survival applies to all histological types of lung cancer. Recent study 
documenting improved survival in women 65 and older with stage I 
and II lung cancer even when untreated suggests that female lung can-
cer has different natural history and potentially different tumor biology. 
Further extensive studies are required to elucidate in women with and 
without exposure to tobacco the biological and genetic role in rela-
tive risk for developing lung cancer, natural history of the primary and 
metastatic malignancy and potential therapeutic advantages. 
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Approximately 10% to 15% of lung cancer patients are never-smokers. 
Lung cancer in never-smokers (LCINS) is more frequently diagnosed 
in women than in men. Toh et al evaluated 883 NSCLC patients diag-
nosed in Singapore between 1999 and 2002. Of 286 never-smokers, 
68.5% were women compared with just 12% women among current 
and former-smokers. However, the fact that there is a signiﬁcantly 
greater proportion of never-smoker women than there are men may 
well contribute to the higher incidence of LCINS observed among 
women. SCLC and squamous cell carcinoma are extremely uncommon 
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histologies in never-smokers, whereas adenocarcinoma is the predomi-
nant cell type.
Few studies focus on risk factors associated with LCINS and even 
fewer evaluate women separately. Although deﬁnitive conclusions 
have yet to be drawn, it has been suggested that risk factors for LCINS 
include environmental tobacco smoke (ETS), exposure to radon, cook-
ing fumes, hormones, human papillomavirus (HPV) infection, inherited 
genetic susceptibility, and diet and physical activity, among others.
- ETS. In a meta-analysis of 19 studies in never-smoker women, the in-
creased lung cancer risk as a result of ETS was estimated to be 20%. In 
a pooled analysis of two large studies, a clear relationship was observed 
between exposure to second-hand smoke from spousal, workplace and 
social sources and the development of LCINS. Gorlova et al performed 
an analysis of potential epidemiologic risk factors for lung cancer using 
data from 280 never-smoker cases. Exposure to ETS was associated 
with signiﬁcantly increased lung cancer risk. 
- Exposure to radon. Radon is a uranium degradation product known 
to be associated with lung cancer in uranium mine workers. The 
majority of the case-control studies conducted in the United States 
support the association between residential radon exposures and 
increased lung cancer risk.
- Cooking fumes. Several case-control studies identify cooking oil 
fumes as a risk factor for lung cancer in Chinese women. Fac-
tors that may play a role include the type of cooking, presence or 
absence of fume extractors, and duration of total cooking years. 
- Hormones. Taioli and Wynder presented evidence that estrogens 
may play a role in the development of lung adenocarcinoma in 
women. Using case-control data they showed that early age at 
menopause was associated with reduced risk of adenocarcinoma of 
the lung, and the use of estrogen replacement therapy was associated 
with a higher adenocarcinoma risk. More recently, Schabath et al 
suggested an association of hormone replacement therapy use with 
a decrease in lung cancer risk. Ganti et al showed that hormone re-
placement therapy was associated with decreased survival in women 
with lung cancer.
- HPV infection. In Taiwanese lung cancer patients, HPV 16/18 DNA 
was detected in 77 (54.6%) of 141 tumor samples. The percentage of 
HPV 16/18 infection among female non-smoker lung cancer patients 
was much higher compared with male non-smoker lung cancer 
patients. The results of this study suggested that HPV infection was 
associated with lung cancer development in non-smoker women. 
- Inherited genetic susceptibility. Few studies have addressed the role 
of inherited susceptibility in LCINS. Gorlova et al evaluated family 
aggregation of lung cancer and other cancers in ﬁrst-degree relatives 
of never-smoker lung cancer patients. The data derived from a lung 
cancer case-control study that included 2,465 ﬁrst-degree rela-
tives of 316 never smoker lung cancer cases and 2,441 ﬁrst-degree 
relatives of 318 never smoker controls. Overall, there was a 25% 
excess risk of any type of cancer among the ﬁrst-degree relatives of 
patients. There was also a 44% excess risk of young onset cancers 
among relatives of patients. Female relatives had a 58% excess 
breast cancer risk. The age at lung cancer diagnosis tended to be ear-
lier in patients’ relatives compared with control relatives. In a Japa-
nese study, the authors investigated 102,255 subjects (48,834 men 
and 53,421 women) with 13 year follow-up during which 791 new 
lung cancer cases were diagnosed. In this study, a family history of 
lung cancer in a ﬁrst-degree relative was associated with a signiﬁ-
cantly increased risk of lung cancer; the association was stronger in 
women than in men, and in never-smokers than in current-smokers. 
- Diet and physical activity. In one study phytoestrogen intake was 
associated with a decrease in lung cancer risk. In a pooled analysis 
of seven cohort studies, the investigators suggested that although 
smoking is the strongest risk factor for lung cancer, greater intake 
of foods high in β-cryptoxanthin, such as citrus fruit, may modestly 
lower the risk. Certain items of diet and physical activity appear to 
be relevant factors, contributing to variations in lung cancer risk 
among women in the Czech Republic.
Tumors from never-smokers are genetically different than those found 
in smokers. The frequency of chromosome alterations is signiﬁcantly 
higher in smokers compared with never-smokers. K-ras and EGFR 
mutations target lung adenocarcinomas, however the subpopula-
tions affected by these mutations are different. The incidence of k-ras 
mutations seems to be correlated with smoking, and being male is also 
considered a related factor. Dutu et al analyzed biomarker expression 
on tissue microarrays in specimens from 190 patients with completely 
resected lung adenocarcinomas (43 never-smokers and 147 smokers). 
High levels of EGFR and KI-67 are observed in smokers, while never-
smokers are characterized by high levels of pAKT and p27. In a multi-
variate model, two biological factors (p27 and KI-67) and two clinical 
factors (age and sex) showed independent signiﬁcant correlation with 
never-smoker status. Liu et al compared the frequencies of the methyl-
ayed promoter of p16 and O6-methylguanine-DNA methyltransferase 
(MGMT) genes in lung tumors from 122 NSCLC patients, including 81 
smokers and 41 never-smokers. The frequency of promoter methyla-
tion was signiﬁcantly higher among smokers, compared with never 
smokers, for both the p16 and MGMT genes. The trend for a higher 
promoter methylation frequency of these genes was also observed 
among women smokers compared with women never-smokers.
The evidence of several studies suggests the possible inﬂuence of 
genetic polymorphisms in the development of LCINS. Glutathione 
S-tranferases detoxify the polycyclic aromatic hydrocarbons found in 
tobacco smoke by glutathione conjugation. In a population-based case-
control study, the authors examined the association among GSTM1, 
GSTT1 and GSTP1 genotypes and LCINS. Overall, there was no sig-
niﬁcant association among single or combination genotypes at GSTM1, 
GSTT1 or GSTP1 and lung cancer risk. However, in never-smokers ex-
posed to 20 or more years of household ETS, carrying the GSTM1 null 
genotype was associated with a 2.3-fold increase in risk. Individuals 
in this high ETS exposure category carrying the GSTM1 null and the 
GSTP1 Val allele were at over 4-fold increased risk of developing lung 
cancer. These ﬁndings suggest that in the presence of ETS, the GSTM1 
genotype both alone and in combination with the GSTP1 genotype can 
inﬂuence the risk of developing lung cancer among never smokers.
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I. Smoking and Tobacco Use Prevalence in Developed and  
Developing Nations 
Tobacco use among women is undergoing dynamic and rapid shifts 
throughout the world. It is estimated that 250 million women (11% of 
women worldwide), compared to almost 1 billion men, in the world are 
daily smokers: 22% in developed nations vs. 9% in developing nations 
(compared to 35% of men vs. 50% of men, respectively). Oral tobacco 
use is far more prevalent in South Asia, and may be as high as 30% in 
women, compared to 25% in men. In many developed nations, notably 
the USA, Canada, the UK and Australia, smoking among women con-
tinues to slowly decline, but in several European countries (southern, 
central and eastern) there has not been a decline and smoking may even 
be increasing. From 1960-2004, smoking prevalence has remained rela-
tively stable in Japan (15%-17%); in the UK, it decreased from 42% 
to 24%; and in the USA it decreased from 34% to 19%. The top ten 
countries with the highest reported smoking rates among women (2005 
or latest available data) are: Cook Islands (71%), Nauru (59%), Guinea 
(47%), Chile (37%), Serbia & Montenegro (34%), Kiribati, FYR 
Macedonia (32%), Lebanon, Tuvalu (31%), and Boznia & Herzegovina 
(30%). The comparison top 10 countries for men are: Yemen (77%), 
Djibouti (75%), Cambodia, China (67%), Kazakhstan, Rep. Korea 
(65%), Armenia (62%), Albania, Russian Federation, Samoa (60%), 
and Guinea (59%).1
Unfortunately, tobacco use among girls is rising worldwide; there were 
no gender differences in smoking among half of the countries surveyed 
in the Global Youth Tobacco Survey, and girls have higher smoking 
rates than boys in some parts of Europe (e.g., Austria, Czech Republic, 
Portugal, Spain, Sweden, Norway) and South America (e.g., Argenti-
na). Factors increasing girls smoking are similar in both sexes: industry 
marketing, easy access, affordability, peer smoking and inﬂuence, 
parental modeling and normative behavior. Both girls and boys still be-
lieve that smoking enhances one’s image and increases popularity; and 
girls smoke to control weight. In many countries, smoking still appears 
in movies, magazines, on billboards and other media targeted to youth 
conveying positive social, physical and style images. Broader buying 
power, women’s emancipation and relaxation of cultural strictures are 
other factors associated with greater female smoking.1 
II. Major Biobehavioral Variables in Women’s Smoking & Tobacco 
Use: Biological Determinants and Social Factors
Among the biological variables determining women’s smoking behav-
ior, nicotine dependence has been most thoroughly explored. Perkins2 
has been the major proponent of the view that women ﬁnd nicotine less 
reinforcing than men and are more responsive to smoking cues, but this 
hypothesis has not been supported by pharmacologic trials that show 
women to be equally responsive to NRT and bupropion (see below). 
There may be gender-speciﬁc genetic variation in nicotine dependence 
among subgroups of women,3 which might account for women with 
greater nicotine dependence having less success in cessation. Depres-
sion and negative affect in general have been considered of greater im-
portance in controlling women’s smoking behavior as well as a number 
of other factors including weight maintenance or loss, and the role of 
hormonal and menstrual factors.4 Pregnancy is considered a “teachable 
moment” for smoking cessation, when many women quit spontane-
ously. However relapse is still very high after childbirth, and successful 
interventions to promote abstinence during childrearing are still much 
needed. Among the social and societal factors affecting smoking, peer 
inﬂuence and norms, parental behavior and approval, perceived risks, 
attitudes and beliefs about smoking, the inﬂuence of media, marketing 
and policy initiatives remain very important, even more in the develop-
ing than in the developed nations.
III. Smoking Cessation
Studies on smoking cessation have largely been conducted in the devel-
oped world. There is a dearth of information on needs assessment and 
cessation in the developing nations.
A. Population-based vs. clinical data: do women have lower quit rates 
than men? 
There is no consistent agreement on whether women have greater dif-
ﬁculty stopping smoking than men. In the USA, population data do not 
demonstrate meaningful gender differences in the percentage of women 
and men current smokers who want to quit (72.2% F vs 68.0%M), and 
who quit for more than one day (41.9%F vs. 40.2%M).5 It has been 
hypothesized that population surveys favoring males over females in 
cessation rates could be accounted for by men switching from ciga-
rettes to other forms of tobacco, such as cigars or snus. Analysis of 
California population prevalence data regarding smoking cessation 
